Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Annals of General Psychiatry

Figure 1

From: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Figure 1

Least-squares (LS) mean Positive and Negative Syndrome Scale (PANSS) total score change from baseline for the paliperidone palmitate dose groups versus placebo group (last-observation-carried-forward [LOCF] analysis). All paliperidone palmitate-treated subjects received paliperidone palmitate 234 mg on day 1 and then received their assigned treatment on days 8, 36, and 64. SE = standard error.

Back to article page